August 23, 2024 07:00 AM EDT
Peer Review

Gen­mab makes two C-suite ad­di­tions as COO leaves; James Sabry leads a re­vamped sup­port­ing cast at Bio­Marin

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ There are sub­stan­tial lead­er­ship changes at Gen­mab, start­ing with the de­par­ture of COO An­tho­ny Manci­ni. Peer Re­view

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times